Metraipolis › archive › dc_de583b0cae85

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events — Europe PMC PMID:42362563

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42362563
DOI
10.1038/s41523-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-10-31T08:43:08.742Z
SHA-256 of the archived text
0ff97377248001f881c43864461ee63a91729bb5e3d5904acdd6755c50273948
Stable URL of this page
https://metraipolis.com/documento/dc_de583b0cae85

How to cite

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events — Europe PMC PMID:42362563 — Europe PMC (en), https://europepmc.org/article/MED/42362563 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_de583b0cae85 (Metraipolis archive dc_de583b0cae85, sha256 0ff97377248001f881c43864461ee63a91729bb5e3d5904acdd6755c50273948)
BibTeX
@misc{dcde583b0cae85,
  title = {Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events — Europe PMC PMID:42362563},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42362563},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_de583b0cae85; sha256 0ff97377248001f881c43864461ee63a91729bb5e3d5904acdd6755c50273948},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42362563. Agents can read the archived copy with the MCP tool read_document.